Irina Pankova, DO
Ophthalmology · Brooklyn, NYNPI 1023023777
Payments from drug & device makers
Across 296 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$939
- Oyster Point Pharma, Inc.$731
- Alcon$595
- Aerie Pharmaceuticals, Inc.$561
- Sun Pharmaceutical Industries Inc.$542
- plus $3K from 13 others
What the payments were for
- Food & beverage$6,82997%
- Education$1402%
- Gifts$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $1,101 |
| Mallinckrodt Hospital Products Inc. | 36 | $939 |
| Oyster Point Pharma, Inc. | 33 | $731 |
| Alcon | 22 | $595 |
| Aerie Pharmaceuticals, Inc. | 16 | $561 |
| Sun Pharmaceutical Industries Inc. | 24 | $542 |
| Bausch & Lomb Americas Inc. | 23 | $475 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $474 |
| Novartis | 18 | $373 |
| Harrow Eye, LLC | 12 | $346 |
| Tarsus Pharmaceuticals, Inc. | 12 | $279 |
| Eyevance Pharmaceuticals LLC | 13 | $263 |
| Thea Pharma Inc. | 4 | $91 |
| Sight Sciences, Inc. | 1 | $79 |
| Dompe US, Inc. | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Biotissue Holdings Inc. | 2 | $41 |
| Akorn Operating Company LLC | 2 | $39 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,033 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alphagan PBrimonidine Tartrate | 453 | $150,295 |
| VyzultaLatanoprostene Bunod | 382 | $147,629 |
| CequaCyclosporine | 257 | $143,296 |
| XiidraLifitegrast | 201 | $138,541 |
| LumiganBimatoprost | 341 | $130,078 |
| MieboPerfluorohexyloctane/Pf | 117 | $126,376 |
| RocklatanNetarsudil Mesylat/Latanoprost | 348 | $121,433 |
| RestasisCyclosporine | 166 | $103,124 |
| XdemvyLotilaner | 40 | $72,261 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 233 | $45,757 |
| RhopressaNetarsudil Mesylate | 134 | $42,410 |
| CombiganBrimonidine Tartrate/Timolol | 103 | $36,274 |
| AzoptBrinzolamide | 89 | $35,952 |
| Brinzolamide | 239 | $35,920 |
| TyrvayaVarenicline Tartrate | 57 | $35,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P, Lumigan, Restasis, Combigan | $1,101 | $419,7711,063 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $475 | $412,546700 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $561 | $163,842482 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $542 | $143,296257 claims |
| AlconSimbrinza, Azopt | $595 | $81,709322 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $279 | $72,26140 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $731 | $35,42657 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet | $474 | $14,35445 claims |
| Thea Pharma Inc.Iyuzeh | $91 | $11,74141 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $263 | $10,47848 claims |
| NovartisTravatan Z | $373 | $6,01213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$250K
- Douglas JabsNew York$24.3M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.